15
Aug

Dutch drug developer ProQR Therapeutics is swinging for a $75 million Wall Street debut to fund its work on a treatment for cystic fibrosis, looking to compete with market leader Vertex Pharmaceuticals.

…read more

Source: CF biotech ProQR shoots for a $75M IPO to challenge Vertex

    

0 No comments